AstraZeneca plc, GlaxoSmithKline plc And The Future Of Pharma

The drugs industry used to be very simple. Companies would invest money in research to develop the next blockbuster drug. Patent protection would mean that these new drugs would provide a steady flow of income to Big Pharma. Much of the increased profit would then be spent on more research. And so we had the virtuous circle of increasing profits and increasing share prices that sustained the industry for years.

Big Pharma must be more creative

But about a decade ago, people started to realise that most of the low-hanging fruit had already been picked. In the 1980s stomach acid treatment Zantac was the best selling drug in the world. Around 2000, Losec was an even bigger seller. But nothing is ever linear. The follow-up medicines to these winners could simply not match their sales.

After all, if a doctor already has a treatment that cures the ailment without side effects, why should he or she spend more on a more recent drug that’s little different? That’s particularly so when the doctor is already familiar with the current medicine and it will soon be off-patent.

This means that Big Pharma is having to be far more creative about how it will generate its profits in coming years.

Today, there are still blockbuster drugs, but they’re biological rather than chemical medicines, based on antibody technologies that are now at the cutting edge of medical science. These treatments are providing step change improvements in diseases such as cancer and arthritis, and they’re a particular strength of AstraZeneca (LSE: AZN).

Adapt and survive

But most firms are finding that they have ageing pharmaceutical portfolios and many of their medicines will be branded and over-the-counter. Here profits will be generated by the quantity sold, rather than by margins. This is an approach that suits companies such as GlaxoSmithKline (LSE: GSK), with its broad portfolio of treatments.

And then there are emerging markets. This is where much of the growth will be as the ever-increasing middle classes of China, India and other emerging markets start to spend much more of their wealth on healthcare. The growing population of this world, and its increasing wealth, means that there will always be a market for the products that AstraZeneca and GlaxoSmithKline make. But we will see a shift in the mix, from the premium end to mass-market and budget treatments.

So the future of pharma is more complex than you might think. It’s no longer a linear game, but more a battle on many fronts. Medical research is advancing very fast. The pharmaceutical industry needs to adapt to advancing science, and a new, rapidly growing market with different priorities and different needs.

Income investing is the at the heart of many small investors' strategies, as it allows you to steadily accumulate and reinvest dividends year-by-year, gradually building your retirement pot.

If you want to learn more about a strong income performer, you should read A Top Income Share From The Motley Fool - it's free of charge and without obligation.

Simply click here now to get your copy. 

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.